Research programme: antisense PTEN gene inhibitors - Isis Pharmaceuticals
Latest Information Update: 17 Sep 2007
At a glance
- Originator Isis Pharmaceuticals
- Class
- Mechanism of Action PTEN inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 17 Sep 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 06 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 13 Jul 2000 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)